Skip to content

OS Therapies OSTX Other Income (Expense)

Other Income (Expense) at other companies

CTO
Citius Oncology, Inc.CTOR
$1.77M+4,003%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$1.28M-16.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$6M-40.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$563M-760%
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
$1.33M-98.5%

Segments

By segment

See full
Chief Operating Decision Maker-$228.89K-120%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's other income (expense)?
OS Therapies (OSTX) reported other income (expense) of -$228.89K in Q1 2026.
How has OS Therapies's other income (expense) changed year-over-year?
OS Therapies's other income (expense) decreased by 120.4% year-over-year, from $1.12M to -$228.89K.
What is the long-term trend for OS Therapies's other income (expense)?
Over 2 years (2023 to 2025), OS Therapies's other income (expense) has grown at a -88.2% compound annual growth rate (CAGR), from -$3.45M to -$48.14K.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.